Abstract: The present invention relates to specific T-cell receptor a-chains, T-cell receptor ?-chains and T-cell receptors comprising said T-cell receptor a-chain and/or ?-chain. In particular, the invention relates to T-cell receptors and/or chains binding to the influenza matrix peptide GILGFVFTL (GL9 peptide) presented by Human Leukocyte antigen A2 (HLA-A2) molecules. The present invention further relates to soluble TCR constructs, chimeric TCRs, nucleic acids, expression constructs and cells comprising said TCR a-chain and/or ?-chain or the respective TCR. The present invention further relates to the use of the TCR a-chain and/or ?-chain or the respective TCR or the soluble TCR constructs or chimeric TCRs as a medicament, preferably in the detection, prevention and/or treatment of influenza. The present invention further relates to methods of detecting, preventing and/or treating influenza.

Abstract: The present invention relates to specific T-cell receptor a-chains, T-cell receptor ?-chains and T-cell receptors comprising said T-cell receptor a-chain and/or ?-chain. In particular, the invention relates to T-cell receptors and/or chains binding to the influenza matrix peptide GILGFVFTL (GL9 peptide) presented by Human Leukocyte antigen A2 (HLA-A2) molecules. The present invention further relates to soluble TCR constructs, chimeric TCRs, nucleic acids, expression constructs and cells comprising said TCR a-chain and/or ?-chain or the respective TCR. The present invention further relates to the use of the TCR a-chain and/or ?-chain or the respective TCR or the soluble TCR constructs or chimeric TCRs as a medicament, preferably in the detection, prevention and/or treatment of influenza. The present invention further relates to methods of detecting, preventing and/or treating influenza.

Abstract: The invention relates to nucleic acid molecules encoding peptides which are directed against autoantibodies associated with cold allergy, to the peptides themselves, to a pharmaceutical composition comprising said nucleic acid molecules and peptides, and to the use of said nucleic acid molecules and peptides for the treatment of circulatory disorders associated with exposure to cold or intolerance to cold, especially cold allergies.

Abstract: A winding device for producing a field coil including a double-layer multiple-circuit winding for an electric motor includes a drive. The drive is configured to operate upon a winding mandrel with multiple lamellas arranged to be swung radially outwardly and inwardly by the drive in order to produce the double-layer multiple-circuit winding as a plurality of winding stacks that are arranged in separate slots and electrically connected in series, in parallel or both. At least two axially-separated winding stacks can be produced at the same time by the drive.

Abstract: The invention relates to a winding device for producing a field coil (30) for an electric machine, especially a field coil (30) having a double-layer multiple-circuit winding, the field coil being formed by a plurality of winding stacks (31a, 32a, 33a . . . 31j, 32j, 33j) that are connected in series and/or in parallel. The inventive device is characterized by a winding mandrel (10) on which at least two axially spaced-apart winding stacks (31a, 32a, 33a) can be produced at the same time.

Abstract: A laser processing system includes a laser processing means, a gas mixing unit, and a controller. The controller controls and adjusts the composition of the process gas for laser processing. The controller includes a data storage for technology tables by means of which the composition of the process gas is controlled and adjusted.

Abstract: The present invention refers to the use of Bob-1 protein, fragments or epitopes thereof and/or related sequences in a method to identify, to induce and/or to isolate Bob-1 specific or Bob-1 cross-reactive T-cells, preferably cytotoxic T-lymphocytes (CTL) and CD4+ T-helper cells. The T-cells according to the invention can be used to identify and diagnose various diseases, which are influenced by Bob-1 protein expression. The invention provides further the use of Bob-1 specific and/or Bob-1 cross-reactive T-cells, as well as peptides and/or nucleic acid sequences for inducing Bob-1 specific and/or Bob-1 cross-reactive T-cells, as medicament or vaccine and for the treatment of Bob-1 expressing tumors, lymphomas and autoimmune diseases.

Abstract: The invention relates to nucleic acid molecules encoding peptides which are directed against autoantibodies associated with cold allergy, to the peptides themselves, to a pharmaceutical composition comprising said nucleic acid molecules and peptides, and to the use of said nucleic acid molecules and peptides for the treatment of circulatory disorders associated with exposure to cold or intolerance to cold, especially cold allergies.

Abstract: Pharmaceutical compositions containing at least one compound of Formula I, ##STR1## where X is a hydrogen atom or both X's represent a direct link between the two sulphur atoms; Y is hydrogen or C.sub.1 -C.sub.6 alkyl and n represents a number from 1 to 10, or their pharmaceutically acceptable salts including .alpha.-lipoic acid and dihydrolipoic acid. The pharmaceutical compositions are useful for the treatment of diseases caused by retroviruses.